Phase 1b RCT | Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial – The Lancet (link to abstract – $ for full-text)

Commentary: Emraclidine is safe and well-tolerated for the treatment of schizophrenia – 2 Minute Medicine

Commentary on Twitter (thread – click for more)

Up to 1/3 of patients with #schizophrenia do not respond to current treatments, and there remains a need for novel approaches that balance efficacy against side-effects.

This phase 1b study assessed the safety and tolerability of emraclidine ? https://t.co/WMcArqDK1C

— The Lancet (@TheLancet) December 28, 2022